A 24-week, multi-centre, open-label, single-arm, phase IV study of the efficacy and safety of Seroquel (quetiapine fumarate) with daily dose 600mg-750mg as mono-therapy in the treatment of acute schizophrenic patients

Trial Profile

A 24-week, multi-centre, open-label, single-arm, phase IV study of the efficacy and safety of Seroquel (quetiapine fumarate) with daily dose 600mg-750mg as mono-therapy in the treatment of acute schizophrenic patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Acronyms SOLO
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Apr 2009 Actual end date (Sep 2007) added as reported by ClinicalTrials.gov.
    • 10 Jun 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
    • 16 Aug 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top